By initiating and then sustaining the thrombotic process without involving the mechanisms of blood clotting, platelet aggregation plays a significant, if not yet fully defined, role in atherosclerosis and its complications. This finding suggests a new focus in therapy: the use of agents that inhibit platelet function (of which several are available) in preference to those that primarily affect coagulation.